NASDAQ
5.27USD
0.00 (0.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
324.5M
P/E
—
EPS
—
Beta
0.43
52W range
2.2-7.95
Day range
5.18–5.45
Open
5.18
Prev close
5.27
Volume
93.7K
Avg volume
393.9K
Dividend
0.00
IPO
2021-02-08
https://www.marketbeat.com/instant-alerts/trisalus-highlights-tumor-treatment-expansion-fda-catalyst-at-growth-conference-2026-08-17/ · 8/18/2026+0.60
https://www.globenewswire.com/news-release/2026/06/23/3316522/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-TriSalus-Life-Sciences-Inc-TLSI.html · 6/23/2026-1.00
https://www.globenewswire.com/news-release/2026/06/17/3313563/0/en/TLSI-Investors-Have-Opportunity-to-Join-TriSalus-Life-Sciences-Inc-Fraud-Investigation-with-the-Schall-Law-Firm.html · 6/17/2026-1.00
https://www.globenewswire.com/news-release/2026/06/05/3307502/0/en/TLSI-INVESTOR-ALERT-Holzer-Holzer-LLC-Investigation-of-TriSalus-Life-Sciences-Inc.html · 6/5/2026-1.00
https://www.globenewswire.com/news-release/2026/06/02/3305649/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-TriSalus-Life-Sciences-Inc-TLSI.html · 6/2/2026-1.00
https://www.newsfilecorp.com/release/298084/Lost-Money-on-TriSalus-Life-Sciences-Inc.-TLSI-Possible-Fraud-Contact-Levi-Korsinsky-Today · 5/19/2026-1.00
https://www.businesswire.com/news/home/20260519640354/en/TLSI-Investor-Alert-Levi-Korsinsky-Investigates-TLSI-TLSI-for-Potential-Securities-Fraud/ · 5/19/2026-1.00
https://www.newsfilecorp.com/release/297675/Investigation-Alert-Biogen-Inc.-BIIB-Under-Scrutiny-Contact-Levi-Korsinsky-for-Details · 5/15/2026-1.00
https://www.newsfilecorp.com/release/297674/Prestige-Consumer-Healthcare-Inc.-PBH-Under-Investigation-for-Potential-Securities-Law-Violations-Contact-Levi-Korsinsky-Today · 5/15/2026-0.50
https://www.prnewswire.com/news-releases/drvn-investor-alert-driven-brands-holdings-inc-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-allegedly-concealing-pervasive-accounting-errors-levi--korsinsky-302716997.html · 3/18/2026-0.80
https://www.prnewswire.com/news-releases/iron-drops-up-to-39-after-fda-crl-for-bitopertin----levi--korsinsky-llp-investigates-302716953.html · 3/18/2026-0.80
https://www.businesswire.com/news/home/20260305831772/en/TriSalus-Life-Sciences-Reports-Fourth-Quarter-and-Year-End-2025-Results-and-Reaffirms-2026-Revenue-Guidance/ · 3/5/2026+0.60
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
